Overview

This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

Eligibility

Inclusion Criteria:

Patient Eligibility

• Patients with symptoms of cystitis and elevated BK virus DNA by screening PCR as above (section 4) post allogeneic HSCT, post chemotherapy
  1. Symptoms of cystitis may include: hematuria (microscopic or gross), pain with urination, frequency, bladder spasms.
  2. Patient may be otherwise treated for cystitis as per local institutional standards. Such treatments may include hydration, antiviral medications, or surgical intervention as deemed appropriate by treating physician.
• Consent: Written informed consent given (by patient or legal representative) prior to

  any study-related procedures.

• Performance Status > 30% (Lansky < 16 yrs and Karnofsky > 16 yrs)
• Age: 0.1 to 25 years
• Females of childbearing potential with a negative urine pregnancy test.

Donor Eligibility

• Related donor available with a T-cell response to the BK-virus MACS® PepTivator® antigen(s).
  1. Original allogeneic donor if available, IgG positive for BKV or confirmatory testing to respond to BKV MACS Peptivator®.
  2. Third Party Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor > 1 HLA A, B, DR match to recipient) with a T-cell response to the BK MACS® PepTivator.

     AND

• Allogeneic donor disease screening is complete similar to hematopoietic stem cell

  donors (Appendix 1).

AND

        • Obtained informed consents by donor or donor legally authorized representative prior to
        donor collection.
        Exclusion Criteria:
        Patient exclusion criteria:
        A patient meeting any of the following criteria is not eligible for the present study:
          -  Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of BK Virus
             CTL infusion
          -  Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of BK Virus
             CTL infusion or within 3 days of planned infusion.
          -  Thymoglobulin (ATG), campath or T cell immunosuppressive monoclonal antibodies within
             30 days
          -  Patient with poor performance status determined by Karnofsky (patients >16 years) or
             Lansky (patients ≤16 years) score ≤30%
          -  Concomitant enrollment in another experimental clinical trial investigating the
             treatment of refractory BK virus infection.
          -  Any medical condition which could compromise participation in the study according to
             the investigator's assessment
          -  Known HIV infection
          -  Female patient of childbearing age who is pregnant or breast-feeding or not willing to
             use an effective method of birth control during study treatment.
          -  Known hypersensitivity to iron dextran
          -  Patients unwilling or unable to comply with the protocol or unable to give informed
             consent.
          -  Known human anti-mouse antibodies